Predict your next investment

Haemonetics company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
haemonetics.com

See what CB Insights has to offer

Investments

1

Partners & Customers

5

Service Providers

2

About Haemonetics

Haemonetics is a medical device company. It had developed the Haemonetics Cell Saver Elite Autotransfusion System.Haemonetics is a global company that markets automated blood processing systems. These systems help increase the safety, quality and availability of the world blood supply by addressing important medical markets: surgical blood salvage, blood component collections and plasma collections.

Haemonetics Headquarter Location

400 Wood Rd. P.o. Box 9114

Braintree, Massachusetts, 02184,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Haemonetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Haemonetics in 2 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

M

Medical Devices

3,500 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Haemonetics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Haemonetics Rank

Latest Haemonetics News

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2022 Results: February 8, 2022

Jan 5, 2022

01/05/2022 | 08:01am EST Message : *Required fields BOSTON, Jan. 5, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, February 8, 2022. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EST on February 8, 2022. The call can be accessed with the following information: U.S. / Canada toll free (877) 848-8880; International (716) 335-9512 Conference ID required for access: 1649685 A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/m6/p/qyrbnnof https://edge.media-server.com/mmc/p/qdj4xoqw A replay of the conference call and webcast will be available for one year beginning on February 8, 2022 at 11:00 a.m. EST using the conference call webcast link provided in this press release. About Haemonetics Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com . Investor Contact:

Haemonetics Investments

1 Investments

Haemonetics has made 1 investments. Their latest investment was in Arryx as part of their Series D on December 12, 2004.

CBI Logo

Haemonetics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/6/2004

Series D

Arryx

$10M

Yes

Date

12/6/2004

Round

Series D

Company

Arryx

Amount

$10M

New?

Yes

Co-Investors

Sources

Haemonetics Acquisitions

4 Acquisitions

Haemonetics acquired 4 companies. Their latest acquisition was Cardiva Medical on January 20, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/20/2021

Series E+

$99M

$176.72M

Acquired

5

4/2/2020

Subscribe to see more

$99M

Subscribe to see more

10

7/18/2006

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

0

9/13/2000

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

1/20/2021

4/2/2020

7/18/2006

9/13/2000

Investment Stage

Series E+

Series D

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

$176.72M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

0

0

Haemonetics Partners & Customers

5 Partners and customers

Haemonetics has 5 strategic partners and customers. Haemonetics recently partnered with Cerus Corporation on December 12, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

12/2/2015

Partner

Cerus Corporation

United States

4

8/20/2015

Partner

Bright Wolf

United States

Subscribe to see more

Subscribe to see more

10

3/5/2015

Client

CSL Plasma

United States

Subscribe to see more

Subscribe to see more

10

10/21/2014

Partner

Paysign

United States

Subscribe to see more

Subscribe to see more

10

Partner

National Patient Safety Foundation

United States

Subscribe to see more

Subscribe to see more

10

Date

12/2/2015

8/20/2015

3/5/2015

10/21/2014

Type

Partner

Partner

Client

Partner

Partner

Business Partner

Cerus Corporation

Bright Wolf

CSL Plasma

Paysign

National Patient Safety Foundation

Country

United States

United States

United States

United States

United States

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Haemonetics Service Providers

2 Service Providers

Haemonetics has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acquired

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Haemonetics Team

22 Team Members

Haemonetics has 22 team members, including current Chief Executive Officer, President, Chris Simon.

Name

Work History

Title

Status

Chris Simon

Chief Executive Officer, President

Current

Bill Burke

Chief Financial Officer

Current

Christopher Lindop

Chief Financial Officer

Current

Anila Lingamneni

Chief Technology Officer, Executive Vice President

Current

Michelle Basil

Executive Vice President

Current

Name

Chris Simon

Bill Burke

Christopher Lindop

Anila Lingamneni

Michelle Basil

Work History

Title

Chief Executive Officer, President

Chief Financial Officer

Chief Financial Officer

Chief Technology Officer, Executive Vice President

Executive Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.